Galactosialidosis

Galactosialidosis is an autosomal recessive inherited lysosomal storage disease caused by biallelic variants in the CTSA gene. This gene encodes cathepsin A or protective protein, necessary for stabilizing β-galactosidase and neuraminidase 1. Its alteration causes a combined deficiency of these enzymes, with accumulation of sialooligosaccharides and other glycoconjugates, leading to progressive multisystemic involvement, especially neurological.

The CTSA gene encodes cathepsin A, also known as protective protein/cathepsin A (PPCA). This protein acts in lysosomes by forming a multienzyme complex with β-galactosidase and neuraminidase 1. Its main function is to protect and stabilize these enzymes so that they can participate correctly in the degradation of glycoproteins, oligosaccharides, and other compounds containing galactose or sialic acid.

When pathogenic variants exist in CTSA, cathepsin A is deficient or unstable, leading to a secondary decrease in the activity of β-galactosidase and neuraminidase 1. As a consequence, undegraded substrates accumulate within the lysosomes of numerous tissues, affecting the central nervous system, skeleton, kidneys, eyes, and other organs. The disease presents a broad clinical spectrum, with early infantile, late infantile, and juvenile/adult forms. It is inherited in an autosomal recessive manner and is an ultrarare condition, with over a hundred cases described; the juvenile/adult form has been observed more frequently in the Japanese population and in some specific family groups.

Symptoms

The age of onset and severity vary by subtype. The early infantile form can manifest from the prenatal or neonatal period with fetal hydrops, hepatosplenomegaly, edema, renal involvement, and severe neurological deterioration. The late infantile form usually appears in the first years of life with coarse facial features, multiple dysostoses, developmental delay, hearing loss, visual disturbances, myoclonus, and seizures. In the juvenile/adult form, which progresses more slowly, ataxia, myoclonus, angiokeratomas, gait disturbances, variable cognitive deficit, and hearing or visual loss may predominate.

Disease management

Currently, there is no approved curative treatment for galactosialidosis. Management is primarily symptomatic and supportive, with multidisciplinary follow-up to control epileptic seizures or myoclonus, and renal, respiratory, ophthalmological, auditory, orthopedic, and nutritional complications. Hematopoietic stem cell transplantation has been attempted in some cases, with variable results and limited benefit on neurological involvement. Gene therapy and other targeted strategies are still under investigation.

Genes analyzed

CTSA U
U Ultra Whole Genome Sequencing 30x

Bibliography

Annunziata I, d'Azzo A. Galactosialidosis: historic aspects and overview of investigated and emerging treatment options. Expert Opin Orphan Drugs. 2017;5(2):131-141.

E O MD, G T, T E, et al. Galactosialidosis in a Newborn with a Novel Mutation in the CTSA Gene Presenting with Transient Hyperparathyroidism. Balkan J Med Genet. 2017 Dec 29;20(2):95-98.

Toki M, Tsunoda K, So T, et al. Juvenile/adult-type galactosialidosis with a homozygous CTSA variant without consanguinity. Hum Genome Var. 2025 Sep 26;12(1):20.

Sharma S, Gupta S, Mehta AP, et al. Infantile Galactosialidosis with Novel Mutation: An Early Presentation. J Pediatr Genet. 2021 Jul 29;12(4):325-328.

Ngiwsara L, Dhachpramuk D, Sawangareetrakul P, et al. Novel CTSA Variant Identified in a Thai Family With Late-Infantile Galactosialidosis. Ann Hum Genet. 2025 May;89(2-3):126-131.

Alsahlawi Z, Alhadi ZJ, Abdulla EA, et al. Galactosialidosis: A Report of Three Cases Diagnosed With a Founder Genetic Mutation in the Bahraini Population. Cureus. 2025 Jan 20;17(1):e77750.

What do your genes say about you? Start your journey today.

Get a special 5% discount on your first kit.

Haven't you taken our DNA test yet?

Get your genetic test and discover what your DNA says about you.

pack
Starter DNA test
The best option to get started

Ancestry service, Traits and Wellness

Buy
pack
DNA test Advanced DNA test
Know your DNA in depth

Health, Ancestry service, Traits and Wellness

Buy
pack
Genetic analysisUltra
Whole Genome Sequencing 30x

Health, Ancestrality, Traits and Wellness

includes three months of tellmeGen+

Buy

Important information and limitations

Europe
Austria
Belgium
Czech Republic
Denmark
Finland
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Poland
Portugal
Romania
Spain
Sweden
Switzerland
United Kingdom
Asia
Kazakhstan
Saudi Arabia
UAE
America
Brazil
Canada
Chile
Colombia
Mexico
Panama
Peru
United States
Oceania
Australia
The Best Prices of the Year! Only until November 27 Use our coupon BLACK15
Buy